The company's increased capital investment hasn't yielded hi...
The company's increased capital investment hasn't yielded higher returns. High current liabilities introduce risk. Investors doubt trend improvement. The stock lacks multi-bagger traits.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment